No change? No chance
EyeWorld Glaucoma Editor Nathan Radcliffe, MD, previews the articles in the Glaucoma section of the issue, specifically highlighting some of the advances and changes coming to the field.
Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
EyeWorld Glaucoma Editor Nathan Radcliffe, MD, previews the articles in the Glaucoma section of the issue, specifically highlighting some of the advances and changes coming to the field.
While modern angle surgery has been a boon for patients and physicians wishing to avoid or delay more invasive glaucoma procedures and/or reduce the number of topical medications, cyclodialysis cleft, while rare, is still a complication that can occur.
In some glaucoma practices, selective laser trabeculoplasty (SLT) has become a mainstay option at various stages of disease and treatment. However, some ophthalmologists say that despite its diverse utility, SLT adoption has been slow in other practices, and a more recent advancement in related technology could increase adoption.
With many expanding technologies in ophthalmology, it makes sense that teaching modalities in the field would expand as well. Anuradha Khanna, MD, created the OcuSim virtual reality training, designed to be used specifically with the Oculus headset, to help teach some of the anatomy and knowledge needed in ophthalmic training.
➤ FDA approves generic Restasis ➤ Phase 3 trial for novel, preservative-free drug delivery platform ➤ Enrollment complete for Phase 3 blepharitis trial ➤ Enrollment complete for Phase 3 mydriasis reversal study ➤ Path forward for resubmission of drug-device combination product ➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report ➤ ASCRS news and events
➤ FDA approves first bispecific antibody for the eye ➤ FDA approves treatment for rare uveal melanoma ➤ New data on clinical programs investigating phentolamine ophthalmic solution ➤ Phase 2 clinical trial results published for investigational drug targeting allergic conjunctivitis ➤ Patient dosing begins for gene therapy to treat X-linked retinitis pigmentosa ➤ New effort to research glaucoma ➤ ASCRS news and events
➤ FDA grants IND for Stargardt gene therapy ➤ Phase 2 clinical trial evaluates oral nicotinamide and pyruvate effect on visual function ➤ First ophthalmic formulation of bevacizumab moves toward FDA BLA submission ➤ Positive results for faricimab as an investigational treatment for wet AMD, DME ➤ Eye scans and AI predict risk of heart attack ➤ ASCRS news and events
➤ FDA clearance for viscodelivery system ➤ FDA approves IND application for immunomodulatory agent for dry eye ➤ Phase 2b results for sustained-release, IOP-lowering implant ➤ Positive topline Phase 2 results for investigational dry eye drug ➤ Phase 2 trials begin for two transdermal drug formulations ➤ Second pivotal trial begins for wet AMD gene therapy ➤ Alcon completes acquisition of Ivantis ➤ ASCRS news and events
➤ FDA approves device to treat MGD ➤ Standalone MIGS device trial begins ➤ Topline results for novel dry eye candidate ➤ Orphan drug designation granted for topical LHON treatment ➤ Positive safety results in Phase 1/2a trial for investigational treatment of wet AMD ➤ Updates on two investigational RNA therapies ➤ ASCRS news and events
➤ New 5-year data with MIGS device ➤ Phase 2 results with new epi-on crosslinking technology ➤ FDA grants IDE, authorizes trial of new viscodilation system ➤ Robotic surgery for glaucoma ➤ First patient dosed in Phase 3 trial of investigational drop for DME ➤ New glaucoma device approved in European market, plus Phase 2 results ➤ ASCRS news and events